Ablynx (BE) – ABLYNX RESPONDS TO PRESS REPORTS
ABLYNX RESPONDS TO PRESS REPORTS
GHENT, Belgium, 22 February, 2010 – Subsequent to various reports in the press, Ablynx can confirm that it is considering raising additional funds through a secondary public offering. No decision has been taken and any final decision to initiate a capital raising will be made subject to market conditions and other factors.
Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. There are four Nanobody-based products currently undergoing clinical trials.